LLY supply chain intelligence for Eli Lilly and Company: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Eli Lilly and Company (LLY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INCY | Incyte Corporation | 95% | Reciprocal relationship from INCY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: ervice institutions, non-profit clinics, and Federal government entities purc… |
| ACRS | Aclaris Therapeutics, Inc. | 92% | Reciprocal relationship from ACRS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS graph: OMERS acquired a portion of the royalty payable by Lilly to us for worldwide … |
| AKTS | Aktis Oncology, Inc. | 92% | Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS gra… |
| BEAM | Beam Therapeutics Inc. | 92% | Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM gra… |
| BOEHRINGER-INGELHEIM | BOEHRINGER-INGELHEIM | 92% | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| BYSI | BeyondSpring Inc. | 92% | Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI gra… |
| VTYX | Ventyx Biosciences Inc | 92% | Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX gra… |
| CHUGAI-PHARMACEUTICAL-CO-LTD | CHUGAI-PHARMACEUTICAL-CO-LTD | 90% | Chugai receives tiered royalty payments on worldwide net sales ranging in percentages from mid single digits to low teens, which we recognize as cost of sales. |
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 90% | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
| GENENTECH-INC | GENENTECH-INC | 90% | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
| TVRD | Tvardi Therapeutics, Inc. | 90% | Reciprocal relationship from TVRD graph: Reciprocal relationship from LLY graph: Reciprocal relationship from TVRD graph: Reciprocal relationship from LLY graph: Reciprocal relationship from TVRD gra… |
| CRNX | Crinetics Pharmaceuticals, Inc. | 85% | Reciprocal relationship from CRNX graph: Radionetics announced the formation of a strategic partnership with Eli Lilly and Company, or Lilly. Under the terms of the agreement, Radionetics received an… |
| OPK | OPKO Health, Inc. | 85% | Reciprocal relationship from OPK graph: Reciprocal relationship from LLY graph: Reciprocal relationship from OPK graph: Reciprocal relationship from LLY graph: Reciprocal relationship from OPK graph:… |
| PRQR | ProQR Therapeutics N.V. | 85% | Reciprocal relationship from PRQR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PRQR graph: — ( ) The effect of changes in foreign exchange rates — — — Other cha… |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACIU gra… |
| ALEC | Alector, Inc. | 72% | Reciprocal relationship from ALEC graph: t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidate… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the ris… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH gra… |
| AXSM | Axsome Therapeutics, Inc. | 72% | Reciprocal relationship from AXSM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AXSM gra… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC gra… |
| BIOA | BioAge Labs, Inc. | 72% | Reciprocal relationship from BIOA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA gra… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: 5,396 2,349 Other operating expenses (739) (720) (288) Operating loss €(181,518) €(53,854) €(61,277) Finance income 4,122 8,046 2,133 Finance expenses (326) (… |
| CRIS | Curis, Inc. | 72% | Reciprocal relationship from CRIS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes pa… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in comb… |
| CTNM | Contineum Therapeutics, Inc. | 72% | Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can … |
| DAWN | Day One Biopharmaceuticals Inc | 72% | Reciprocal relationship from DAWN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from DAWN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from DAWN gra… |
| DSGN | Design Therapeutics, Inc. | 72% | Reciprocal relationship from DSGN graph: riffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively m… |
| ECOR | electroCore, Inc. | 72% | Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR gra… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary … |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our cu… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $281,860 across 2 awards. 36C25026N0080 AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN; 36C26226N0579 F-18 AMYVID B+4 | Qwen corre… |
| ACIU | AC Immune SA | 92% | Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA, are intended to facilitate expeditious executio… |
| BOEHRINGER-INGELHEIM | BOEHRINGER-INGELHEIM | 92% | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| IMRX | Immuneering Corporation | 92% | Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: In August 2025, we announced a clinical supply agreement with Eli Lilly and C… |
| INCY | Incyte Corporation | 92% | Reciprocal relationship from INCY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: entered into a license, development and commercialization agreement with Eli … |
| MCK | McKesson Corporation | 92% | Reciprocal relationship from MCK graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MCK graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MCK graph:… |
| SPRB | Spruce Biosciences, Inc. | 92% | Reciprocal relationship from SPRB graph: Pursuant to the terms of the Lilly License Agreement, Lilly granted us an exclusive, worldwide, royalty bearing, sublicensable license under certain technolog… |
| UTHR | United Therapeutics Corporation | 92% | Reciprocal relationship from UTHR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from UTHR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from UTHR gra… |
| ALMIRALL-S-A | ALMIRALL-S-A | 90% | We receive tiered royalty payments on net sales in Europe ranging in percentages from low double digits to low twenties, which we recognize as collaboration and other revenue. |
| FHTX | Foghorn Therapeutics Inc. | 90% | Reciprocal relationship from FHTX graph: Concurrent with the Lilly Collaboration Agreement, we also entered into a stock purchase agreement (the "Lilly SPA") with Lilly whereby we issued and sold Lil… |
| TNGX | Tango Therapeutics, Inc. | 90% | Reciprocal relationship from TNGX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from TNGX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from TNGX gra… |
| ACRS | Aclaris Therapeutics, Inc. | 80% | Reciprocal relationship from ACRS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS gra… |
| CYPH | Cypherpunk Technologies Inc. | 80% | Reciprocal relationship from CYPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYPH gra… |
| AKTS | Aktis Oncology, Inc. | 72% | Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS gra… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of the Jardiance produ… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of the Jardiance product family in the most significant markets and recognize the royalty as collaborat… |
| ATOS | Atossa Therapeutics, Inc. | 72% | Reciprocal relationship from ATOS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ATOS gra… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC gra… |
| BEAM | Beam Therapeutics Inc. | 72% | 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basa… |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi,… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi,… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basa… |
| BYSI | BeyondSpring Inc. | 72% | Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI gra… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CAH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CAH graph:… |
| CAH | Cardinal Health, Inc. | 72% | ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., social media) with information about our… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: s while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the … |
| CYCN | Cyclerion Therapeutics, Inc. | 72% | Reciprocal relationship from CYCN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protectio… |
| ECOR | electroCore, Inc. | 72% | Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the p… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LLY-DEBT | Debt stack $54.9B | 90% | Market cache reports total debt of $54.9B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LLY-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 4359 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BIOA | BioAge Labs, Inc. | 100.00 | 1 | ['supplier'] |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 1 | ['supplier'] |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 1 | ['customer', 'supplier'] |